A Longer Acting Rfviii, Safe And Effective

BLOOD（2014）

Cited 10|Views4

No score

Abstract

In this issue of Blood, Mahlangu et al describe a well-designed and executed phase 3 multicenter study of a recombinant factor VIII (rFVIII) product fused with the Fc fragment of immunoglobulin G1 (IgG1) in 165 patients with severe hemophilia A.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined